Showing results (61-70 of 76) with videos related to
Sort By:
Pageof 8
Cancers|July 16, 2020
A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue SarcomasVarun Monga, Keith M Skubitz, Seth Maliske, et al.Gynecologic Oncology|June 28, 2017
Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trialMartee L Hensley, Shreyaskumar R Patel, Margaret von Mehren, et al.Cancer Research Communications|March 16, 2023
Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with MelanomaRobert H I Andtbacka, Yan Wang, Robert H Pierce, et al.Journal for Immunotherapy of Cancer|July 31, 2021
Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trialVarun Monga, Benjamin J Miller, Munir Tanas, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II TrialEzra E W Cohen, Lisle Nabell, Deborah J Wong, et al.Journal for Immunotherapy of Cancer|June 12, 2021
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanomaYousef Zakharia, Robert R McWilliams, Olivier Rixe, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2015
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical TrialGeorge D Demetri, Margaret von Mehren, Robin L Jones, et al.JCO Oncology Advances|May 7, 2025
Phase II Study of Pexidartinib Plus Sirolimus in Unresectable Malignant Peripheral Nerve Sheath Tumors Identifies M2 Macrophage ActivationGulam A Manji, Liam J Stanton, Angela C Hirbe, et al.Sarcoma|May 14, 2020
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the LungKristin Baird, John Glod, Seth M Steinberg, et al.The New England Journal of Medicine|June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanomaKeith T Flaherty, Caroline Robert, Peter Hersey, et al.Pageof 8